moneyheap
GOSS · Analysis updated Jul 28, 2026, 2:30 AM ET
Why is Gossamer Bio, Inc. Common Stock (GOSS) stock moving?
Gossamer Bio (GOSS) has experienced a dramatic shift in momentum following a critical regulatory and corporate update on July 27, 2026. After months of uncertainty caused by the Phase 3 PROSERA study narrowly missing its primary statistical threshold (p=0.032 vs alpha=0.025), the FDA has clarified that this miss is a "review issue" rather than a "filing issue," permitting a New Drug Application (NDA) submission in September 2026. Market data reflects this optimism, with volume exploding to over 328,000 shares on July 27—a tenfold increase over the previous average—sending the price from $0.136 to $0.199. Furthermore, the company successfully reduced its debt principal by $115.9 million and reacquired full worldwide rights to seralutinib. While the financial position remains tight with $57 million in cash, the consolidated ownership and clear regulatory roadmap have fundamentally improved the stock's risk-reward profile, despite the impending dilution from a reverse stock split.
News behind the analysis
- Gossamer Bio to Submit Seralutinib NDA in September 2026Following a Pre-NDA Type B meeting, the FDA confirmed that the Phase 3 PROSERA study results are review issues rather than filing barriers, clearing the way for a September submission.
- Gossamer Reacquires Worldwide Rights to Seralutinib from ChiesiGossamer Bio has terminated its collaboration with Chiesi, regaining full global development and commercial rights to its lead PAH candidate while receiving a $5 million settlement payment.
- Stockholders Approve Convertible Note Exchange and Reverse SplitShareholders voted to reduce debt by $115.9 million through a note exchange and authorized a reverse stock split to maintain Nasdaq listing compliance.
- GOSS Stock Surges 44% on Regulatory Path ClarityThe stock price jumped significantly on July 27 following news that the FDA will accept the NDA filing despite the primary endpoint miss in the Phase 3 PROSERA study.
- stockscan.ioSource identified via Google Search grounding.
- quartr.comSource identified via Google Search grounding.
- biospace.comSource identified via Google Search grounding.
- seekingalpha.comSource identified via Google Search grounding.
- marketbeat.comSource identified via Google Search grounding.
- tipranks.comSource identified via Google Search grounding.
- stocktitan.netSource identified via Google Search grounding.
- zacks.comSource identified via Google Search grounding.
- allsci.comSource identified via Google Search grounding.